Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
L-Base Co. Ltd. holds a patent portfolio situated in the Biotechnology & Pharmaceuticals technology area. Prosecution activity is currently limited to 1 pending office action. This matter is being handled by 1 distinct examiner working within a distinct art unit. This level of concentration is typical for companies focusing on a specific pharmaceutical candidate or a specialized biotechnological process.
NIEBAUER, RONALD T is the busiest examiner for the company, with the busiest examiner pending office action. For a portfolio in the Biotechnology & Pharmaceuticals field, this concentration indicates a specific or early-stage prosecution phase. The pending office action defines the current trajectory for the company's intellectual property efforts. Practitioners should focus on the specific requirements of this examiner, as there are no other active filings to provide a broader view of the company's standing at the patent office. The outcome of this action will be the primary indicator of the portfolio's success in the near term.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996875 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | NIEBAUER, RONALD T | 81d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996875 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | NIEBAUER, RONALD T | 1658 | §103Other | Non-Final OA | 81d overdue | Pending | Oct 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial